Testosterone propionate, for intramuscular injection, contains testosterone propionate which is the oil-soluble 4-androstene-3-one,17beta-ol of the androgenic hormone testosterone. Testosterone propoinate is attached to a short ester. Thus, 100mg of testosterone propionate contains 83.72mg of testosterone, more testosterone than in any other ester-based testosterone preparation of equivalent overall dosage. Testosterone propionate is used in males to treat primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. In females: metastatic mammary cancer. Testosterone propionate converts into estrogens and DHT.

Drostanolone propionate is an injectable anabolic/androgenic steroid (AAS). It is highly androgenic and mildly anabolic. Drostanolone does not aromatize into estrogens and has similar properties to dihydrotestosterone (DHT). Drostanolone originally was developed to be used as an anti-estrogenic compound for treating female breast cancer. Drostanolone is irreversibly metabolized by the enzyme 3a-hydroxysteroid-dehydrogenase into an inactive form of 2α-methyl-5α-androstan-3α-ol-17-one

Trenbolone acetate (TBA), an androgenic/anabolic steroid (AA), is a potent agonist of androgen receptors and has been extensively used as a growth promoter. TBA is a progestin and does not convert to estrogens. The effects of TBA are increased weight gain, improved food conversion efficiency, decreased muscle RNA and DNA concentrations, and decreased free cathepsin D activity in muscle. The half-life of trenbolone acetate in circulation is one day.